Opinion|Videos|September 3, 2025

Discussing Baricitinib for Alopecia Areata

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment for severe alopecia areata (AA).

Video content above is prompted by the following:

  1. McMichael: Baricitinib became the first systemic treatment for severe AA after the BRAVE-AA1 and BRAVE-AA2 phase 3 trials were released. What did the data show in terms of safety and efficacy that led to FDA approval in 2022?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo